INGN$6.88
Chart
Performance
Key Stats
AI INGN Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldInogen Inc. shows resilience with positive short-term technical indicators, but faces significant headwinds from recent performance and profitability challenges. Long-term prospects depend on a turnaround in its core business and effective cost management.
Thematic
The company operates in the growing medical technology sector, specifically respiratory health, which has favorable long-term demographic trends. However, current market dynamics and the company's competitive positioning require careful observation.
Fundamental
Inogen demonstrates fluctuating revenue and negative earnings, indicating profitability challenges. While its balance sheet remains relatively stable with a good cash position, consistent free cash flow generation is a concern.
Technical
The stock is showing signs of a short-term recovery, trading above key moving averages. However, momentum indicators suggest caution, and a significant move would require breaking strong resistance levels.
| Factor | Score |
|---|---|
| Aging Population & Respiratory Illnesses | 85 |
| Medical Device Innovation | 60 |
| Reimbursement & Regulatory Landscape | 40 |
| Direct-to-Consumer vs. B2B Channels | 55 |
| Economic Sensitivity | 45 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 20 |
| Growth | 50 |
| Balance Sheet Health | 85 |
| Cash Flow | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 75 |
| Momentum | 60 |
| Volume Confirmation | 65 |
| Support & Resistance | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Improved Profitability and Positive Adjusted EBITDA
Inogen reported a 64% improvement in GAAP net loss for Q1 2025 compared to the prior year, and achieved positive adjusted EBITDA of $36,000 in Q1 2025, a significant turnaround from a negative $7.6 million in the prior period. [2, 25]
Consistent Revenue Growth Driven by B2B Segment
Inogen delivered over $82 million in revenue for Q1 2025, reflecting a 5.5% year-over-year growth. The company also saw a 29.9% increase in domestic business-to-business revenue and a 22.9% increase in international business-to-business revenue. [2, 17]
Bearish Points (6)
Persistent Net Losses and Negative Margins
Despite improvements, Inogen continues to report GAAP net losses and negative net margins (-10.69% in 2024), indicating ongoing profitability challenges. [2, 25]
Margin Pressure from Shift to Private Payers
The shift in customer mix towards private payers, which have lower billing rates, along with changes in the sales team, has led to a decline in direct-to-consumer sales and put pressure on gross margins. [25]
Calendar
August 2025
8
Next Earnings Date
H: $-0.09
A: $-0.09
L: $-0.09
H: 91.00M
A: 90.60M
L: 90.00M
Profile
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One and Inogen Rove, an ambulatory solutions for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Seasonals
Price Target
11.67 USD
The 39 analysts offering 1 year price forecasts for INGN have a max estimate of 14.00 and a min estimate of 9.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor to Inogen in the portable and stationary oxygen concentrator market, with a broad respiratory product portfolio.
Weight: 90
A major player in sleep and respiratory care, offering a wide range of oxygen therapy devices and cloud-connected solutions, directly competing with Inogen's focus.
Weight: 88
Parent company of CAIRE Inc., a leading global supplier and direct competitor in the oxygen concentrator market, also involved in medical gas solutions.
Weight: 85
Direct competitor specializing in high-flow nasal cannula (HFNC) therapy systems and devices for respiratory support, a segment related to oxygen therapy.